Xtant Medical Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
XTNT$0.27-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net income (loss) | $4,973 | $(16,449) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 5,223 | 4,224 |
| Non-cash interest | 537 | 522 |
| Loss (gain) on sale of fixed assets | 251 | (264) |
| Stock-based compensation | 2,892 | 4,117 |
| Provision for reserve on accounts receivable | 1,404 | 823 |
| Provision for excess and obsolete inventory | 3,669 | 485 |
| Gain on divestiture | (3,281) | — |
| Other | (76) | (5) |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (591) | (755) |
| Inventories | (1,999) | (2,494) |
| Prepaid and other assets | (1,537) | (218) |
| Accounts payable | (3,117) | 1,033 |
| Accrued liabilities | 4,198 | (2,915) |
| Net cash provided by (used in) operating activities | 12,546 | (11,896) |
| Investing activities: | ||
| Purchases of property and equipment | (2,382) | (4,113) |
| Proceeds from sale of fixed assets | 232 | 383 |
| Proceeds from divestiture | 10,049 | — |
| Net cash provided by (used in) investing activities | 7,899 | (3,730) |
| Financing activities: | ||
| Borrowings on line of credit | 100,066 | 112,640 |
| Repayments on line of credit | (101,329) | (105,142) |
| Payments on long-term debt | (8,000) | — |
| Payments on financing leases | (67) | (65) |
| Proceeds from private placement, net of issuance costs | (65) | 4,456 |
| Proceeds from issuance of long-term debt | — | 5,000 |
| Debt issuance costs | (49) | (651) |
| Payment of taxes from withholding of common stock upon vesting and settlement of restricted stock units | (126) | (178) |
| Proceeds from exercise of stock-based compensation | — | 13 |
| Net cash (used in) provided by financing activities | (9,570) | 16,073 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 232 | (149) |
| Net change in cash and cash equivalents and restricted cash | 11,107 | 298 |
| Cash and cash equivalents and restricted cash at beginning of year | 6,221 | 5,923 |
| Cash and cash equivalents and restricted cash at end of year | $17,328 | $6,221 |
| Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets | ||
| Cash and cash equivalents | $17,053 | $6,199 |
| Restricted cash | 275 | 22 |
| Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets | $17,328 | $6,221 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.